{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:42:22Z","timestamp":1775562142255,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.clml.2021.09.001","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T20:00:55Z","timestamp":1632340855000},"page":"158-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1303-0447","authenticated-orcid":false,"given":"Alexander","family":"Spira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Gnanasakthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7460-5198","authenticated-orcid":false,"given":"Rafael","family":"Curiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Radford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.09.001_bib0001","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.clml.2021.09.001_bib0002","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/asheducation-2017.1.284","article-title":"Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?","volume":"2017","author":"Davies","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2021.09.001_bib0003","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.001_bib0004","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bjh.14453","article-title":"Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era","volume":"176","author":"Vardhana","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.09.001_bib0005","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.09.001_bib0006","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.001_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/147176","article-title":"The development and validation of a measure of health-related quality of life for Non-Hodgkin's lymphoma: the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)","volume":"54","author":"Hlubocky","year":"2013","journal-title":"Lymphoma"},{"key":"10.1016\/j.clml.2021.09.001_bib0008","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"10.1016\/j.clml.2021.09.001_bib0009","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/cncr.31133","article-title":"Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy","volume":"124","author":"Pearman","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.09.001_bib0010","year":"2020","journal-title":"FDA-ASCO Public Workshop: 2020 Clinical Outcome Assessments in Cancer Clinical Trials"},{"key":"10.1016\/j.clml.2021.09.001_bib0011","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.09.001_bib0012","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2018-99-112878","article-title":"The burden of relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): a systematic literature review (SLR)","volume":"132","author":"Lenz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.001_bib0013","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","article-title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma","volume":"25","author":"Maziarz","year":"2020","journal-title":"Blood. Adv"},{"key":"10.1016\/j.clml.2021.09.001_bib0014","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/bjh.16300","article-title":"Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study","volume":"189","author":"Thieblemont","year":"2020","journal-title":"Br J Haem"},{"issue":"15(suppl)","key":"10.1016\/j.clml.2021.09.001_bib0015","doi-asserted-by":"crossref","first-page":"e20070","DOI":"10.1200\/JCO.2020.38.15_suppl.e20070","article-title":"Health-related quality of life (HRQOL) burden in patients with relapsed\/refractory diffuse large B-cell lymphoma (RR-DLBCL) and non-Hodgkin's lymphoma (RR-NHL)","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.001_bib0016","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2018.6205","article-title":"Investigating potential bias in patient-reported outcomes in open-label cancer trials","volume":"5","author":"Roydhouse","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2021.09.001_bib0017","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1182\/blood.V112.11.2376.2376","article-title":"Validation of the functional assessment of cancer therapy-lymphoma (FACT-Lym) in patients with relapsed\/refractory mantle cell lymphoma","volume":"112","author":"Carter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.001_bib0018","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00277-016-2878-5","article-title":"Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone","volume":"96","author":"Cheson","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.09.001_bib0019","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021020310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021020310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:46Z","timestamp":1761871066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021020310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2152265021020310"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.09.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ADC Therapeutics. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}